AstraZeneca Challenge To Medicare Drug Price Program Fails

By Dan McKay · March 1, 2024, 1:50 PM EST

A Delaware federal judge on Friday rejected AstraZeneca's challenge to the Medicare price negotiation program, upholding the Biden administration's argument that the talks are voluntary....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

AstraZeneca Pharmaceuticals LP v. Becerra et al

Case Number

1:23-cv-00931

Court

Delaware

Nature of Suit

Other Statutes: Administrative Procedures Act/Review or Appeal of Agency Decision

Date Filed

August 25, 2023

Recent Articles By Dan

November 19, 2024
No 'Tin Hats': Fluoride Ruling Offers Options As RFK Eyes Ban
November 15, 2024
Teva Defends Mifepristone Antitrust Case Against Corcept
November 12, 2024
Wash. Ballot Win Gives States Blueprint For 'Age Wave' Care
November 06, 2024
Voters Pass Medicaid Tax In Calif., Support IVF Coverage In Ill.
November 05, 2024
Biotech, Pharma Cos. Eye Impact Of DOJ's Foreign Data Rule
October 31, 2024
Beverly Hills Agrees To Abortion-Rights Training In Settlement
October 29, 2024
4th Circ. Quizzes Drugmaker Challenging W.Va. Abortion Law
October 29, 2024
Beyond Abortion, 7 Ballot Questions Set To Shape Care
October 23, 2024
NC Justices Scrutinize Scope Of Liability Shield In COVID Law
October 22, 2024
Drug-Shortage List Under Scrutiny After FDA Reversal